DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Mepolizumab is an investigational drug.
There have been 44 clinical trials for Mepolizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2018.
The most common disease conditions in clinical trials are Asthma, Syndrome, and Hypereosinophilic Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, St. Joseph's Healthcare Hamilton, and National Institute of Allergy and Infectious Diseases (NIAID).
There are twenty-seven US patents protecting this investigational drug and three hundred and eighty international patents.
Recent Clinical Trials for Mepolizumab
|Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial||GlaxoSmithKline||Phase 2/Phase 3|
|Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial||Leicester Clinical Trials Unit||Phase 2/Phase 3|
|Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial||University of Leicester||Phase 2/Phase 3|
Top disease conditions for Mepolizumab
Top clinical trial sponsors for Mepolizumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Mepolizumab||See Pricing||Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders||Knopp Biosciences LLC (Pittsburgh, PA)||See Pricing|
|Mepolizumab||See Pricing||Compositions comprising oxo-derivatives of fatty acids and methods of making and using same||DS BIOPHARMA LIMITED (Dublin, IE)||See Pricing|
|Mepolizumab||See Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Pricing|
|Mepolizumab||See Pricing||Compositions and methods for treating chronic urticaria||Knopp Biosciences LLC (Pittsburgh, PA)||See Pricing|
|Mepolizumab||See Pricing||Soft lozenge compositions||Patheon Softgels, Inc. (High Point, NC)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|